NCT02978755 - First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 10, 2020

Study Completion Date

June 10, 2020

Conditions

Neoplasm, Gynecologic

Interventions

DRUG

GM102

GM102 escalating doses (phase1)

DRUG

GM102 escalating doses

GM102 escalating doses combined with paclitaxel and carboplatin

DRUG

GM102

GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)

Trial Locations (12)

Institut Bordet, Brussels

UZ Leuven, Leuven

CHU Besançon, Besançon

Institut Bergonié, Bordeaux

Centre Oscar Lambret, Lille

Centre Leon Berard, Lyon

Institut de cancerologie de Montpellier, Montpellier

Institut de cancerologie de Lorraine, Nancy

Institut Curie, Paris

Institut Universitaire Cancer Toulouse - Oncopole, Toulouse

Gustave Roussy, Villejuif

Royal Marsden Hospital, London